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(DAS28)Abstract Aim of the work: Proteinase-activated receptor 2 (PAR2) is a G protein-coupled recep-
tor activated by serine proteinases with proinﬂammatory activity. The aim of this work was to eval-
uate the expression of PAR2 on peripheral blood monocytes and T-cells in rheumatoid arthritis
(RA) patients and its correlation with disease activity.
Patients and methods: Forty RA patients and 16 healthy controls were enrolled in this study.
Flow cytometry was performed to detect PAR2 expression. Disease activity score (DAS28) was
assessed.
Results: PAR2 expression was signiﬁcantly higher on monocytes in RA patients with active dis-
ease compared with patients in remission and healthy controls (75.4 ± 7.68; 56 ± 13.93 and
46.5 ± 9.8 respectively; p< 0.001). It was higher in RA patients in remission compared to healthy
control (p= 0.01). No signiﬁcant difference was found between patients with moderate and high dis-
ease activity. It signiﬁcantly correlated with the erythrocyte sedimentation rate (ESR) and DAS28
(p< 0.001). It was signiﬁcantly higher in patients with rheumatoid factor (RF) and anti-cyclic citrul-
linated peptide (anti-CCP) positivity (p= 0.01, p< 0.001, respectively). It was not signiﬁcantly
associated with C-reactive protein (CRP) positivity and was not signiﬁcantly different between early
and long standing RA patients. PAR2 expression on CD3+ T-cells was not signiﬁcantly different
between patients with RA disease activity, patients in remission and healthy controls. Also it was
not signiﬁcantly associated with the ESR, DAS28, anti-CCP, RF and CRP positivity.
Conclusion: PAR2 expression on monocytes is consistent with a pathogenic role for PAR2 in RA
and suggests that PAR2 may have utility as a marker for RA disease activity.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).enouﬁa,
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Rheumatoid arthritis (RA) is a chronic inﬂammatory multisys-
tem disorder affecting primarily cartilage and joints, which
aetiopathogenesis has not been clariﬁed yet. The synovial
inﬂammation and destruction of joints are often progressive
and lead to joint destruction. As a result of cell-mediated
immune response, the condition is characterized by secretion
of different inﬂammatory products from activated lympho-
cytes, macrophages, ﬁbroblasts and leukocytes in synovial
joints [1].
Proteinase-activated receptors are a novel family of seven-
transmembrane G protein coupled receptors uniquely acti-
vated by proteinase cleavage of the receptor N terminus,
revealing an activating ligand that binds to the extracellular
loop-2 of the receptor [2,3]. Proteinase-activated receptor 2
(PAR2) is a member of this family with putative proinﬂam-
matory roles which remain poorly deﬁned in human diseases.
Selective activation of PAR2 promotes joint swelling and
synovial hyperaemia in mice [4] and has been shown to
promote cytokine release from human cell lines in vitro [5].
PAR2 was shown to be upregulated in synovium from
patients with RA and a selective PAR2 antagonist substan-
tially inhibited generation of tumor necrosis factor (TNF-a)
from RA synovial membrane digests [6]. Previous studies
in healthy subjects found low [7] or no [8] PAR2 surface
expression in CD14+ cells from freshly drawn blood,
although there appeared to be intracellular stores of PAR2
[7]. CD3+ T cells and CD34+ stem cells also did not show
signiﬁcant cell surface PAR2 expression [7]. These various
studies suggest that, normally, relatively little PAR2 is
expressed on peripheral blood mononuclear cells.
The aim of this study was to evaluate the expression of
proteinase-activated receptor 2 on peripheral blood mononu-
clear cells in patients with rheumatoid arthritis and its correla-
tion with disease activity.2. Patients and methods
The present study was conducted on 40 RA patients attend-
ing the out-patient clinic of Physical medicine,
Rheumatology and Rehabilitation department, Menouﬁa
University Hospitals diagnosed according to ACR/EULAR
classiﬁcation criteria 2010 [9] and 16 age and sex matched
healthy controls. Disease activity score in 28 joints
(DAS28), was evaluated in RA patients [10]. Twenty
patients were in disease activity (DAS28P 2.6) (19 females
and 1 male, their ages ranged from 22 to 61 years, disease
duration ranged 5 months-30 years) and 20 were in disease
remission (DAS28 < 2.6) (18 females and 2 males, their ages
ranged from 30 to 65 years, disease duration ranged
8 months-25 years). No juvenile onset RA cases were
included. Patients with disease activity were further subdi-
vided into 3 subgroups; low, moderate and high disease
activity. This study was approved by the ethics committee
of the Faculty of Medicine, Menouﬁa University. All
patients provided signed informed consent to provide a
blood sample and to review the medical record for research
purposes.2.1. Immunophenotyping of peripheral blood monocytes and T-
cells
Peripheral blood mononuclear cells were isolated by density
gradient centrifugation and the mononuclear cell layer was
then transferred to a fresh tube and the cells washed three times
in phosphate buffered saline. The cells were incubated in FcR
blocking reagent (polyclonal human IgG, Miltenyi Biotec
GmbH, Germany) for 10 min at 4 C to prevent non-speciﬁc
binding of antibodies to cells via Fc regions. The mononuclear
cells were then incubated with FITC-conjugated antihuman
CD3 (Immunostep, Spain) and PE-conjugated antihuman
PAR2 (R&D systems, Minneapolis, MN 55413) for 30 min at
4 C followed by washing with PBS. Cell acquisition and anal-
ysis were done using BD FACSCalibur ﬂow cytometry (BD
Biosciences, Franklin Lakes, New Jersey, USA). We gated on
monocytes and CD3+ cells and then analyzed the percentage
of monocytes and T cells expressing PAR2 and PAR2mean ﬂu-
orescent intensity ratio (MFIR) was measured within these
population. Controls and patient samples were examined using
the same settings and conditions for comparison.
2.2. Statistical analysis
Analysis was performed with SPSS version 20 statistical soft-
ware. Quantitative data were expressed as mean ± standard
deviation (X ± SD) and analyzed by applying t-test for com-
parison of two groups of normally distributed variables; two
groups of non-normally distributed variables were tested by
applying the Mann–Whitney test. Comparisons of three
groups of normally distributed variables were done by an
Anova test and three groups of non-normally distributed vari-
ables by applying Kruskal–Wallis Test. Post hoc test is used
after Anova (F test) or Kruskal–Wallis test to show any signif-
icant difference between the individual groups. Qualitative
data were expressed as number and percentage (No & %)
and analyzed by applying chi-square test. Pearson correlation
was used for normally distributed quantitative variables, while
Spearman correlation was used for non-normally distributed
quantitative variables or when one of the variables is qualita-
tive. P value < 0.05 was considered statistically signiﬁcant.
3. Results
Forty RA patients and 16 age and sex matched healthy
controls were included in this analysis. The descriptive clinical
and laboratory data of the studied groups of patients and
control are shown in Tables 1 and 2.
On peripheral blood monocytes, the percentage expressing
PAR2 was signiﬁcantly higher in patients with RA disease
activity compared with patients in remission and healthy con-
trols (p< 0.001) (Table 3 and Figs. 1 and 2). It was also signif-
icantly increased in patients with remission compared to
healthy controls (p= 0.01). Regarding PAR2 mean ﬂuores-
cent intensity ratio (MFIR) on monocytes; there were signiﬁ-
cantly higher levels in active RA patients compared with the
healthy controls (p< 0.001) (Table 3 and Fig. 1). However
by post hoc test, there was no signiﬁcant difference when com-
paring patients in activity and remission (p= 0.06) and
patients in remission and healthy controls (p= 0.34).
Table 1 Demographic and laboratory features in the rheumatoid arthritis (RA) patients and controls and the disease duration and
activity in RA patients.
Characteristics RA patients (n= 40) Control (n= 16) Signiﬁcance
In activity (n= 20) In remission (n= 20) Test p
Age (years) 45.1 ± 10.7
(22–61)
45.4 ± 9.2
(30–65)
43.5 ± 9.7
(30–62)
0.2 0.83
Sex
Male 1 (5) 2 (10) 3 (18.8) 1.8 0.41
Female 19 (95) 18 (90) 13 (81.2)
Disease duration
Early 12 (60) 11 (55) – 0.1 0.74
Long standing 8 (40) 9 (45)
DAS28 5.47 ± 0.98 (3.85–7.34) 2.31 ± 0.21 (1.9–2.53) – – –
ESR (mm/1st hr) 57.4 ± 26.4 (15–120) 17.9 ± 4.4 (10–23) 12.6 ± 3.2 (9–20) – –
CRP positivity 16 (80) 8 (40) 0 (0) 23.3 <0.001*
RF positivity 20 (100) 12 (60) 0 (0) 36.4 <0.001*
Anti-CCP positivity 20 (100) 9 (45) 0 (0) 36.2 <0.001*
RA: rheumatoid arthritis, early: disease duration 6 2 years, long standing: disease duration > 2 years, DAS28: disease activity score in 28
joints, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, RF: rheumatoid factor, anti-CCP: anti-cyclic citrullinated peptide. Data
are expressed as mean ± SD (range) or n (%).
* Signiﬁcantly different.
Table 2 Demographic, clinical and laboratory features in the rheumatoid arthritis (RA) patients according to disease activity.
Characteristics Active RA patients (n= 20) Signiﬁcance
Moderate (n= 8) High (n= 12) Test p
Age (years) 48.1 ± 8.04 (22–61) 43 ± 12.1 (30–65) 0.7 0.48
Sex
Male 0 (0) 1 (8.3) 0.04 0.83
Female 8 (100) 11 (91.7)
Disease duration
Early 5 (62.5) 7 (58.3) 0.08 0.78
Long standing 3 (37.5) 5 (41.7)
DAS28 4.6 ± 0.4 (3.9–5.1) 6.1 ± 0.8 (5.2–7.3) – –
ESR (mm/1st hr) 37.1 ± 13.9 (15–55) 70.8 ± 24.1 (34–120) – –
CRP positivity 5 (62.5) 11 (91.7) 1.1 0.3
RF positivity 8 (100) 12 (100)
Anti-CCP positivity 8 (100) 12 (100)
RA: rheumatoid arthritis, moderate: DAS28 (3.2–5.1), high: DAS28 (>5.1). Early: disease duration 6 2 years, long standing: disease dura-
tion > 2 years, DAS28: disease activity score in 28 joints, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, RF: rheumatoid
factor, anti-CCP: anti-cyclic citrullinated peptide. Data are expressed as mean ± SD (range) or n (%).
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activity yielded no signiﬁcant difference regarding both the
percentage of monocytes expressing PAR2 and PAR2 MFIR
(p> 0.05) (Table 4). Both PAR2 and PAR2 MFIR expression
on monocytes were found to be signiﬁcantly higher in patients
with RF (p= 0.01 for both) and anti-CCP positivity
(p< 0.001, p= 0.03 respectively) while they were not signiﬁ-
cantly different between CRP negative and positive patients
(Table 5) or between early and long standing RA patients; in
early RA patients (n= 23) the PAR2% was 66.91 ± 14.18
and the PAR2 MFIR was 5.78 ± 2.51. In those with long
standing RA (n= 17) PAR2% was 64.05 ± 15.95 and
PAR2 MFIR was 4.74 ± 1.58 (p> 0.05).
On T cells, no signiﬁcant differences were found between
patients in activity, patients in remission and healthy controls
regarding the percentages of CD3+ T-cells expressing PAR2 aswell as the PAR2MFIR (p> 0.05) (Table 3 and Figs. 1 and 2).
Also PAR2 expression on CD3+ T-cells did not signiﬁcantly
differ between patients with moderate and high disease activity
(p> 0.05) (Table 4). Both PAR2 and PAR2 MFIR expression
on CD3+ T-cells were not signiﬁcantly associated with RF,
anti-CCP and CRP positivity (p> 0.05) (Table 5) and were
not signiﬁcantly different between early (n= 23) and long
standing (n= 17) RA patients; in early RA patients PAR2%
was 10.46 ± 6.83 and PAR2 MFIR was 2.05 ± 0.75. In long
standing RA, PAR2% was 12.11 ± 6.87 and PAR2 MFIR
2.39 ± 1.05 (p> 0.05).
There was a signiﬁcant correlation between both PAR2 and
PAR2 MFIR expression on monocytes with the ESR
(p< 0.001) and the DAS28 score (p< 0.001, p= 0.01 respec-
tively) (Fig. 3) while there was no signiﬁcant correlation with
those expressed on the CD3+ T-cells (p> 0.05).
Table 3 Comparison between RA patients with disease activity, with remission and healthy controls regarding PAR2 expression on
monocytes and CD3+ T-cell.
PAR2 expression mean ± SD (range) RA patients (n= 40) Control (n= 16) Signiﬁcance
In activity (n= 20) In remission (n= 20) Test p
On monocytes
PAR2% 75.4 ± 7.7 (63–93) 56 ± 13.9 (30–75) 46.5 ± 9.8 (30–60) 33.8 <0.001
MFIR 6.1 ± 2.3 (3–13.5) 4.6 ± 1.8 (2–11.2) 3.8 ± 0.99 (0.74–5) 14.1 0.001
On CD3+ T cells
PAR2% 11.1 ± 7.2 (2–29) 11.3 ± 6.6 (2–26) 7.9 ± 4.4 (2–18) 2.6 0.27
MFIR 2.4 ± 1.1 (0.95–5.2) 2.02 ± 0.7 (0.95–3.5) 2.2 ± 0.8 (0.95–3.6) 0.7 0.69
RA: rheumatoid arthritis, PARS2: Proteinase-activated receptor 2, MFIR: mean ﬂuorescent intensity ratio, CD: cluster of differentiation.
Figure 1 PAR2 expression on monocytes and CD3+ T-cells (both percent and MFIR).
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Proteinase-activated receptor 2 (PAR2) is expressed on the
synovial lining, bone, and cartilage of articular joints and
may be proinﬂammatory by promoting protease-dependent
catabolic tissue damage [11,12], synovial hyperplasia, ﬁbrosis[13,14], and the development of chronic inﬂammatory diseases
like rheumatoid arthritis [4,6,15–17]. It has been demonstrated
that PAR2 mediates plasma extravasation, inﬂammatory cell
diapedesis [18–20], and activation of mast cells [16,21–23],
which are all associated with arthritis and similar chronic
inﬂammatory conditions. Increased PAR2 expression occurs
Table 4 Comparison between RA patients with moderate and
high disease activity regarding PAR2 expression on monocytes
and CD3+ T-cell.
PAR2 expression
mean ± SD (range)
Active RA patients
(n= 20)
Signiﬁcance
Moderate
(n= 8)
High
(n= 12)
Test p
On monocytes
PAR2% 75.9 ± 8.8
(63–91)
75.1 ± 7.3
(65–93)
0.19 0.84
MFIR 6.2 ± 1.9
(3–8.6)
6.1 ± 2.6
(3.6–13.5)
0.77 0.43
On CD3+ T cells
PAR2% 11.3 ± 6.1
(4–20)
10.9 ± 8.1
(2–29)
0.34 0.72
MFIR 2.5 ± 1.3
(0.95–5.2)
2.3 ± 0.97
(1.1–4.4)
0.23 0.81
RA: rheumatoid arthritis, PARS2: proteinase-activated receptor 2,
MFIR: mean ﬂuorescent intensity ratio, CD: cluster of differenti-
ation. Moderate: DAS28 (3.2–5.1), high: DAS28 (>5.1).
Table 5 Association between PAR2 expression and rheuma-
toid factor, anti-CCP and CRP positivity in RA patients.
Parameter
mean ± SD
PAR2 expression in RA patients (n= 40)
On monocytes On CD3+ T cells
PAR2% MFIR PAR2% MFIR
RF
+ve (32) 68.4 ± 13.6 5.7 ± 2.3 11.3 ± 7.3 2.2 ± 0.96
ve (8) 54.8 ± 15.3 3.9 ± 1 10.5 ± 4.7 2.2 ± 0.6
p-Value 0.01* 0.01* 0.95 0.56
Anti-CCP
+ve (29) 70.6 ± 12.2 5.8 ± 2.4 11.2 ± 7.04 2.2 ± 0.96
ve (11) 52.8 ± 13.7 4.2 ± 0.8 11.1 ± 6.5 2.1 ± 0.7
p-Value 0.001* 0.03* 0.96 0.94
CRP
+ve (24) 67.7 ± 14.6 5.18 ± 2.4 10.7 ± 6.7 2.2 ± 0.8
ve (16) 62.7 ± 15.2 5.6 ± 1.99 11.8 ± 7.2 2.2 ± 1.1
p-Value 0.19 0.41 0.66 0.86
PAR2: proteinase-activated receptor 2, MFIR: mean ﬂuorescent
intensity ratio, CD: cluster of differentiation, RF: rheumatoid
factor, anti-CCP: anti-cyclic citrullinated peptide, CRP: C-reactive
protein.
* Signiﬁcantly different.
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human RA and animal models of arthritis [4,6,11,12,15,16].
PAR2-knockout mice have been reported to be resistant to
antigen-induced arthritis [4,15]. It was shown that activation
of PAR2 results in proinﬂammatory reactions via the produc-
tion of cytokines, such as IL-6, IL-8, and prostaglandin [7,24].
It was also reported that PAR2 activation induces production
of IL-1b and Intercellular adhesion molecule (ICAM)-1 by
lung epithelial and umbilical vein endothelial cells [25].
Those reports suggested that PAR2 activation may be associ-
ated with local increases in serine proteases that inducecytokine-related inﬂammation. Microarray experiments
suggest that circulating RA monocytes are not normal [26].
Here we investigate whether PAR2 expression is increased in
peripheral blood mononuclear cells derived from patients with
RA and its correlation with disease activity.
In this study, the percentage of monocytes expressing
PAR2 was signiﬁcantly lower in healthy controls than in
RA patients. Previous studies have shown that CD14+
monocytes have little PAR2 surface expression in healthy
subjects [7,8,27]. In RA patients the percentage of mono-
cytes expressing PAR2 was signiﬁcantly higher in patients
with disease activity than those with remission, however it
did not differ signiﬁcantly between those with high and
moderate disease activity. This result was in agreement with
those reported by Crilly et al. [27], who found that patients
with RA ﬂare showed higher surface PAR2 expression than
those in remission. Comparing between patients with RA
activity and those with remission using PAR2 MFIR showed
no signiﬁcance between them. This was in contrast to
ﬁndings reported by Crilly et al. [27], who found that
PAR2 MFIR was higher in active RA patients.
On CD3+ T-cells, no signiﬁcant differences were found
between patients with activity, patients with remission and
healthy controls regarding both the percentage of expressing
PAR2 and the PAR2 MFIR. These ﬁndings were in contrast
to those reported by Crilly et al. [27], who found that RA
patients showed varied PAR2 expression on CD3+ T-cells that
differed signiﬁcantly from the healthy controls and patients
with RA ﬂare showed higher surface PAR2 expression than
those in remission.
In this study, signiﬁcant correlation was found between
PAR2 expression on monocytes and ESR and DAS28 score
which was in agreement with ﬁndings reported by Crilly
et al. [27]. This suggests that PAR2 is associated with general
pathological disease activity mechanisms. While no signiﬁcant
association was found between PAR2 expression on mono-
cytes and CRP positivity which was in contrast to Crilly
et al. [27] ﬁndings. Also no signiﬁcant correlation was found
between PAR2 expression on CD3+ T-cells and ESR, DAS
28 score and CRP positivity. This came in contrast to Crilly
et al. [27] ﬁndings, who reported signiﬁcant correlation
between them. Signiﬁcant association between higher levels
of PAR2 expression on monocytes and anti-CCP and RF
positivity was also found.
The observation that leucocytes have substantial intracellu-
lar stores of PAR2 [7] suggests that this system is ‘primed’ so
that there are intracellular pools of PAR2 protein available
to be recruited to the membrane once triggered. Factors which
regulate the movement of PAR2 to the cell surface are still not
well understood.
The protein-coding oncogene Rab11a has been shown to
promote trafﬁcking of PAR2 from intracellular stores in the
Golgi apparatus to the cell surface [28] although how this is
achieved remains poorly understood. Better understood are
the mechanisms underlying PAR2 internalisation and degra-
dation [29,30]. Although not all the links in the chain
responsible for PAR2 upregulation on the cell surface are
known, it has been upregulated in human umbilical vein
endothelial cells by various cytokines including TNFa [31]
and that interferon c can increase its expression in neu-
trophils from healthy donors [32]. Under these conditions,
it is not unreasonable to speculate that elevated levels of
Figure 2 Representative dot plot for Flow cytometric analysis of PAR2 expression on monocytes and T cells for healthy controls and
RA patients.
96 S.H. Kandel et al.plasma TNF in RA patients [33] could be responsible for
the increased PAR2 expression on the surface of CD14+
cells.In conclusion, our data provide further compelling evidence
for dysregulation of the PAR2 pathway in RA, and suggest that
PAR2 may have utility as a marker for RA disease activity.
Figure 3 Correlation between PAR2 expression on monocytes (both percent & MFIR) with ESR levels and DAS28 score.
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